DOP2012000265A - Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores. - Google Patents

Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores.

Info

Publication number
DOP2012000265A
DOP2012000265A DO2012000265A DO2012000265A DOP2012000265A DO P2012000265 A DOP2012000265 A DO P2012000265A DO 2012000265 A DO2012000265 A DO 2012000265A DO 2012000265 A DO2012000265 A DO 2012000265A DO P2012000265 A DOP2012000265 A DO P2012000265A
Authority
DO
Dominican Republic
Prior art keywords
robo1
fusion protein
tumor treatment
protein
slit
Prior art date
Application number
DO2012000265A
Other languages
English (en)
Inventor
Francis Blanche
Beatrice Cameron
Tarik Dabdoubi
Pierre Fons
Jean-Pascal Herault
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000265(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2012000265A publication Critical patent/DOP2012000265A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA PROTEÍNA RECOMBINANTE ROBO1-FC Y SU UTILIZACIÓN PARA TRATAR LAS ENFERMEDADES EN LAS QUE SE SOBREEXPRESA UNA PROTEÍNA SLIT, EN PARTICULAR CÁNCER. SE REFIERE IGUALMENTE A UNA COMPOSICIÓN QUE COMPRENDE TAL PROTEÍNA RECOMBINANTE. OTRO ASPECTO DE LA INVENCIÓN CONSISTE EN LA UTILIZACIÓN DE UNA MOLÉCULA ROBO1-FC COMO HERRAMIENTA DE DIAGNÓSTICO PARA DETECTAR LA SOBREEXPRESIÓN DE UNA MOLÉCULA DE LA FAMILIA SLIT EN UN PACIENTE.
DO2012000265A 2010-04-14 2012-10-05 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores. DOP2012000265A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
DOP2012000265A true DOP2012000265A (es) 2013-02-28

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000265A DOP2012000265A (es) 2010-04-14 2012-10-05 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores.

Country Status (26)

Country Link
US (1) US9493529B2 (es)
EP (1) EP2558489A1 (es)
JP (1) JP5858442B2 (es)
KR (1) KR20130059329A (es)
CN (1) CN102884076A (es)
AR (1) AR080891A1 (es)
AU (1) AU2011239839B2 (es)
BR (1) BR112012026020A2 (es)
CA (1) CA2796303A1 (es)
CL (1) CL2012002879A1 (es)
CR (1) CR20120508A (es)
DO (1) DOP2012000265A (es)
EA (1) EA201291044A1 (es)
EC (1) ECSP12012230A (es)
FR (1) FR2958936A1 (es)
GT (1) GT201200275A (es)
IL (1) IL222382A (es)
MA (1) MA34221B1 (es)
MX (1) MX338981B (es)
NI (1) NI201200155A (es)
PE (1) PE20130199A1 (es)
SG (1) SG184529A1 (es)
TN (1) TN2012000473A1 (es)
TW (1) TW201142024A (es)
UY (1) UY33334A (es)
WO (1) WO2011128561A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
RS58517B1 (sr) 2012-01-05 2019-04-30 Boston Medical Ct Corp Slit-robo signalizacija za dijagnostiku i lečenje bolesti bubrega
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
MX2019014480A (es) 2017-06-02 2020-01-23 Pfizer Proteinas recombinantes robo2, composiciones, metodos y usos de las mismas.
WO2019038772A1 (en) 2017-08-24 2019-02-28 Bar-Ilan University ROUNDABOUT FAMILY RECEPTOR INHIBITORS (ROBO) AND CORRESPONDING USES THEREOF
CA3136663A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Compositions and methods useful in promoting milk production

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
ATE245190T1 (de) * 1997-10-20 2003-08-15 Univ California Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
WO1999051625A2 (en) * 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
EP1307557A2 (en) * 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
SI1572169T1 (sl) 2002-03-08 2013-12-31 Shanghai Institutes For Biological Sciences, Cas Odkrivanje in modulacija slit in robo posredovane angiogeneze ter njuni načini uporabe
US20080153104A1 (en) * 2003-08-08 2008-06-26 Hiroyuki Aburantai Gene Overexpressed in Cancer
JP2008504012A (ja) * 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質
CA2911000A1 (en) * 2006-04-05 2007-10-18 Min W. Wan Antibody purification
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
EP2150562A1 (en) * 2007-04-27 2010-02-10 Genetech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
NO2195023T3 (es) 2007-08-29 2018-08-04
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof

Also Published As

Publication number Publication date
GT201200275A (es) 2014-01-24
AU2011239839B2 (en) 2015-08-20
FR2958936A1 (fr) 2011-10-21
JP5858442B2 (ja) 2016-02-10
AR080891A1 (es) 2012-05-16
JP2013523172A (ja) 2013-06-17
PE20130199A1 (es) 2013-03-09
IL222382A0 (en) 2012-12-31
CR20120508A (es) 2012-11-01
WO2011128561A1 (fr) 2011-10-20
MA34221B1 (fr) 2013-05-02
US20130039912A1 (en) 2013-02-14
ECSP12012230A (es) 2012-11-30
TN2012000473A1 (fr) 2014-01-30
UY33334A (es) 2011-12-01
MX2012011822A (es) 2012-11-12
IL222382A (en) 2016-06-30
TW201142024A (en) 2011-12-01
US9493529B2 (en) 2016-11-15
KR20130059329A (ko) 2013-06-05
SG184529A1 (en) 2012-11-29
NI201200155A (es) 2013-02-05
CL2012002879A1 (es) 2013-03-22
CA2796303A1 (fr) 2011-10-20
EA201291044A1 (ru) 2013-04-30
CN102884076A (zh) 2013-01-16
EP2558489A1 (fr) 2013-02-20
AU2011239839A1 (en) 2012-11-08
MX338981B (es) 2016-05-06
BR112012026020A2 (pt) 2016-06-28

Similar Documents

Publication Publication Date Title
DOP2012000265A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
BR112012012918A2 (pt) agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes.
GT201200315A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
IN2014MN02069A (es)
GT201200172A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
UY35147A (es) Anticuerpos anti-ceacam5 y usos de éstos.
CR20110509A (es) Composicion farmaceutica
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112012030479A2 (pt) terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112017018522A2 (pt) composições e métodos para diagnóstico e tratamento do câncer
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
EP3001813A4 (en) Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
HK1232242A1 (zh) 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物
BR112013016107A2 (pt) molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
BR112013024265A2 (pt) peptídeo cíclico, uso de peptídeos cíclicos, método para o tratamento de doenças, composição farmacêutica, composto para o diagnóstico de câncer, e, combinação farmacêutica
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer